ConductScience.org, home

Paper894339

Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors.

Levin VA and 5 others. J Neurosurg, 1977. Cited by 207 papers, by iCite.

Cite this record

ConductScience Library. Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors. Papers, record 894339. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/894339

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Criteria for evaluating patients undergoing chemotherapy for malignant brain tumors.
PubMed
Journal
J Neurosurg
PubMed
Year
1977
PubMed
Publication types
Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
207
iCite
Relative citation ratio, by iCite
6.28
iCite
Revised in PubMed
2022-04-09
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Levin VAV A
2Crafts DCD C
3Norman DMD M
4Hoffer PBP B
5Spire JPJ P
6Wilson CBC B

Source PubMed

Download CSV of authors

Topics8

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Brain NeoplasmsMajor topic
Antineoplastic Agents
Electroencephalography
Humans
Prognosis
Retrospective Studies
Time Factors
Tomography, X-Ray Computed

Source PubMed

Download CSV of topics

Cited by72

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 207 citations.

PMIDTitleJournalYearIn PapersSource
41325560STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.J Clin Oncol2026https://conductscience.org/library/papers/41325560PubMed
40586994RANO 2.0: critical updates and practical considerations for radiological assessment in neuro-oncology.Jpn J Radiol2025https://conductscience.org/library/papers/40586994PubMed
38968207Evaluating soluble Axl as a biomarker for glioblastoma: A pilot study.PLoS One2024https://conductscience.org/library/papers/38968207PubMed
38170429Updated Response Assessment in Neuro-Oncology (RANO) for Gliomas.Curr Neurol Neurosci Rep2024https://conductscience.org/library/papers/38170429PubMed
37515669Phase II study of border zone stereotactic radiosurgery with bevacizumab in patients with recurrent or progressive glioblastoma multiforme.J Neurooncol2023https://conductscience.org/library/papers/37515669PubMed
36858729Harnessing imaging tools to guide immunotherapy trials: summary from the National Cancer Institute Cancer Imaging Steering Committee workshop.Lancet Oncol2023https://conductscience.org/library/papers/36858729PubMed
36386035Relationship between RANO-PRO Working Group standardised priority constructs and disease progression among malignant glioma patients: A retrospective cohort study.EClinicalMedicine2023https://conductscience.org/library/papers/36386035PubMed
35451676Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory.Neurotherapeutics2022https://conductscience.org/library/papers/35451676PubMed
33634034A Position Statement on the Utility of Interval Imaging in Standard of Care Brain Tumour Management: Defining the Evidence Gap and Opportunities for Future Research.Front Oncol2021https://conductscience.org/library/papers/33634034PubMed
32190946Emerging MRI Techniques to Redefine Treatment Response in Patients With Glioblastoma.J Magn Reson Imaging2020https://conductscience.org/library/papers/32190946PubMed
32133275Objective response rate assessment in oncology: Current situation and future expectations.World J Clin Oncol2020https://conductscience.org/library/papers/32133275PubMed
31386050Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.Neurooncol Pract2019https://conductscience.org/library/papers/31386050PubMed
31133966Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse.Front Neurol2019https://conductscience.org/library/papers/31133966PubMed
30806082Use of the Response Assessment in Neuro-Oncology (RANO) criteria in clinical trials and clinical practice.CNS Oncol2019https://conductscience.org/library/papers/30806082PubMed
30411280Brain tumour post-treatment imaging and treatment-related complications.Insights Imaging2018https://conductscience.org/library/papers/30411280PubMed
30258190Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients.Sci Rep2018https://conductscience.org/library/papers/30258190PubMed
29897562Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.Neuro Oncol2018https://conductscience.org/library/papers/29897562PubMed
29378419Clinical importance of eflornithine (α-difluoromethylornithine) for the treatment of malignant gliomas.CNS Oncol2018https://conductscience.org/library/papers/29378419PubMed
29218626Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.Clin Transl Oncol2018https://conductscience.org/library/papers/29218626PubMed
29040703Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma.Neuro Oncol2018https://conductscience.org/library/papers/29040703PubMed

See all 72 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/894339

GET https://conductscience.org/api/papers/v1/894339/cited_by?page=2